Nu-Med Plus (Nu-Med Plus) Cash, Cash Equivalents, Marketable Securities : $0.01 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus Cash, Cash Equivalents, Marketable Securities?

Nu-Med Plus's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then stayed the same from Dec. 2023 ($0.01 Mil) to Mar. 2024 ($0.01 Mil).

Nu-Med Plus's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($0.01 Mil) to Dec. 2022 ($0.07 Mil) but then declined from Dec. 2022 ($0.07 Mil) to Dec. 2023 ($0.01 Mil).

Nu-Med Plus Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Nu-Med Plus's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus Cash, Cash Equivalents, Marketable Securities Chart

Nu-Med Plus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.01

0.19

0.01

0.07

0.01

Nu-Med Plus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.05	0.03	0.01	0.01	0.01

Nu-Med Plus Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Nu-Med Plus (OTCPK:NUMD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Nu-Med Plus Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nu-Med Plus (Nu-Med Plus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777

Website

https://www.nu-medplus.com

Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.

Executives

William C Hayde	director, officer: CEO	76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith	10 percent owner	P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl	director, officer: VP of Medical Marketing	P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen	officer: CFO, Sec, Treas, Prin Acct Off	455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait	10 percent owner	514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison	director, 10 percent owner, officer: Vice President of Technology	975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon	director, 10 percent owner, officer: Vice President of Operations	1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins	director, 10 percent owner, officer: CEO	455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111